Magnetic fluid hyperthermia has been recently considered as a Renaissance of cancer treatment modality due to its remarkably low side effects and high treatment efficacy compared to conventional chemotheraphy or radiotheraphy. However, insufficient AC induction heating power at a biological safe range of AC magnetic field ( H appl · f appl < 3.0–5.0 × 10 9 A m −1 s −1 ), and highly required biocompatibility of superparamagnetic nanoparticle (SPNP) hyperthermia agents are still remained as critical challenges for successful clinical hyperthermia applications. Here, newly developed highly biocompatible magnesium shallow doped γ‐Fe 2 O 3 (Mg 0.13 ‐γFe 2 O 3 ) SPNPs with exceptionally high intrinsic loss power (ILP) in a range of 14 nH m 2 kg −1 , which is an ≈100 times higher than that of commercial Fe 3 O 4 (Feridex, ILP = 0.15 nH m 2 kg −1 ) at H appl · f appl = 1.23 × 10 9 A m −1 s −1 are reported. The significantly enhanced heat induction characteristics of Mg 0.13 ‐γFe 2 O 3 are primarily due to the dramatically enhanced out‐of‐phase magnetic susceptibility and magnetically tailored AC/DC magnetic softness resulted from the systematically controlled Mg 2+ cations distribution and concentrations in octahedral site Fe vacancies of γ‐Fe 2 O 3 instead of well‐known Fe 3 O 4 SPNPs. In vitro and in vivo magnetic hyperthermia studies using Mg 0.13 ‐γFe 2 O 3 nanofluids are conducted to estimate bioavailability and biofeasibility. Mg 0.13 ‐γFe 2 O 3 nanofluids show promising hyperthermia effects to completely kill the tumors.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2017) studied this question.